Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer: A multi-centre retrospective analysis.
Sarah Hunter(Guy's and St Thomas' NHS Foundation Trust), Eleni Karapanagiotou(King's College London), Nadia Yousaf(Royal Marsden Hospital), Tom Newsom-Davies(Chelsea and Westminster Hospital), James Spicer(King's College London), Gillian Brand(Aberdeen Royal Infirmary), Guillermina Nickless(Guy's Hospital), Michael Neat(Guy's Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Daniel Smith(Guy's and St Thomas' NHS Foundation Trust), M. Nicolson, Karim El-Shakankery(University College Hospital)
Cited by 1
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614